Related Experiment Video
Updated: Mar 15, 2026
Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
Published on: May 10, 2022
Commentary on "Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents"
1Department of Cell & Molecular Pharmacology & Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina. tewk@musc.edu.
Abstract:
The relatively recent clinical success of bortezomib, particularly in multiple myeloma, has established the validity of the proteasome as a viable target for anticancer drug development. This highly cited 1999 Cancer Research article from Adams and colleagues was published during the period when this drug was transitioning from preclinical studies to phase I clinical trial status. Their results detail structure-activity analyses using a series of boronic acid proteasome inhibitors and correlate cytotoxicity with inhibition of proteasome activity. In and of itself, the recognition that interference with proteasome functions represented a novel therapeutic approach likely underlies the popularity of this article. In addition, the provision of in vitro (at that time using the NCI 60 cell line panel) and in vivo antitumor activity, toxicology, and mouse pharmacokinetic and pharmacodynamic data provided a solid basis for establishing the future credentials for bortezomib to gain initial FDA approval in 2003. Cancer Res; 76(17); 4916-7. ©2016 AACRSee related article by Adams et al., Cancer Res 1999;59:2615-22Visit the Cancer Research 75(th) Anniversary timeline.
Insights
This study highlights proteasome inhibitors, like bortezomib, as effective anticancer drugs. It details structure-activity relationships and demonstrates preclinical efficacy, paving the way for clinical trials and FDA approval.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The proteasome is a validated target for anticancer drug development, evidenced by bortezomib's success in multiple myeloma.
- This 1999 Cancer Research article was pivotal during bortezomib's transition from preclinical to clinical development.
Purpose of the Study:
- To analyze the structure-activity relationships of boronic acid proteasome inhibitors.
- To correlate the cytotoxicity of these inhibitors with their ability to inhibit proteasome activity.
- To provide preclinical data supporting bortezomib as a novel therapeutic approach.
Main Methods:
- Structure-activity analysis of novel boronic acid proteasome inhibitors.
- In vitro studies using the NCI 60 cell line panel.
- In vivo antitumor activity, toxicology, and pharmacokinetic/pharmacodynamic assessments in mice.
Main Results:
- Established a correlation between proteasome inhibition and cytotoxicity.
- Demonstrated in vitro and in vivo antitumor efficacy of boronic acid derivatives.
- Provided essential preclinical data including toxicology and pharmacokinetics.
Conclusions:
- Interference with proteasome function is a viable anticancer therapeutic strategy.
- The presented data supported bortezomib's progression to clinical trials and eventual FDA approval.
- This work established the foundation for proteasome inhibitor-based cancer therapies.
Related Concept Videos
02:18The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
01:13The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
02:18The Proteasome
01:15Drugs that Stabilize Microtubules
01:10Drugs that Destabilize Microtubules
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...